GeneDx
WGS | NASDAQ
$51.02
-$1.35 (-2.58%)
At close: Nov 16, 2026, 4:00 PM ET
$51.00
-$0.02 (-0.04%)
After-hours:
Nov 16, 2026, 7:47 PM ET
GeneDx Company Profile
Company profile explainedCompany Profile
GeneDx Holdings Corp., a genomics company, provides genetic testing services. The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. It also develops an AI-based platform for next generation sequencing analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing. GeneDx Holdings Corp. was founded in 2000 and is headquartered in Stamford, Connecticut.
Key Executives
| Name | Position |
|---|---|
| Katherine A. Stueland | Chief Executive Officer & Director |
| Heidi C. Chen | Chief Legal Officer |
| Jami Biliboaca | Chief People Officer |
| Kevin Feeley | Chief Financial Officer |
| Bryan Dechairo | Chief Technology & Innovation Officer |
| Linda Genen | Chief Medical Officer |
| Lisa Gurry | Chief Business Officer |
| Mark A. Gardner | President |
| Melanie Duquette | Chief Growth Officer |
| Sabrina Dunbar | Director of Investor Relations & Communications |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 18, 2026 | 4 | Filing |
| Sep 18, 2026 | 4 | Filing |
| Sep 18, 2026 | 4 | Filing |
| Sep 11, 2026 | 4 | Filing |
| Sep 11, 2026 | 4 | Filing |
| Sep 03, 2026 | 4 | Filing |
| Sep 01, 2026 | 144 | Filing |
| Sep 01, 2026 | 144 | Filing |
| Aug 11, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Aug 07, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
GeneDx
| Country | United States |
| IPO Date | Nov 4, 2020 |
| Industry | Medical - Diagnostics & Research |
| Sector | Healthcare |
| Employees | 1,300 |
| CEO | Katherine A. Stueland |
Contact Details
North Tower Stamford,
Connecticut 06902 United States
Stock Details
| Ticker Symbol | WGS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001818331 |
| CUSIP Number | 81663L200 |
| ISIN Number | US81663L2007 |
| SIC Code | 8000 |
Recent News
- 5 days ago / businesswire.comGeneDx to Participate in Upcoming Investor Conferences
- 6 days ago / fool.comWhy GeneDx Holdings Stock Just Dropped 16.6%
- 7 days ago / seekingalpha.comGeneDx Holdings Corp. (WGS) Q3 2026 Earnings Call Transcript
- 7 days ago / seekingalpha.comGeneDx: Q3 Earnings Indicate Transition To Sustained Profitability
- 7 days ago / marketbeat.comGeneDx Q3 Earnings Call Highlights
- 7 days ago / zacks.comGeneDx Holdings Corp. (WGS) Tops Q3 Earnings and Revenue Estimates
- 12 days ago / businesswire.comGeneDx and Mirum Pharmaceuticals Launch Sponsored Testing Programs to Help Patients Find Answers Through Comprehensive Genetic Testing
- 20 days ago / prnewswire.comDid GeneDx Holdings Corp. Insiders Breach their Fiduciary Duties to Shareholders?
- 24 days ago / businesswire.comGeneDx to Report Third Quarter 2026 Financial Results on Monday, November 9, 2026
- 28 days ago / businesswire.comGeneDx Advances Clinical Adoption of Genomic Medicine with 27 Abstracts at ASHG 2026
Add to Watchlist
Select watchlists to add or remove WGS